PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Contraceptive safety among women with cystic fibrosis: a systematic review.

Abstract With dramatic improvements in life expectancy for cystic fibrosis (CF) patients, contraception for women with CF has become an important issue. There are theoretical concerns that hormonal contraceptive use among women with CF may impact disease severity or risk for other adverse health outcomes, including thrombosis and poor bone health, as well as concerns that malabsorption or altered drug metabolism might impact contraceptive effectiveness.
PMID
Related Publications

Steroidal contraceptives and bone fractures in women: evidence from observational studies.

Combined hormonal contraceptive use among women with known dyslipidemias: a systematic review of critical safety outcomes.

Combined hormonal contraceptive use among breastfeeding women: an updated systematic review.

Contraceptive use among women with inflammatory bowel disease: A systematic review.

Contraceptive use among women with multiple sclerosis: a systematic review.

Authors

Mayor MeshTerms
Keywords

Contraception

Cystic fibrosis

Effectiveness

Safety

Systematic review

Journal Title contraception
Publication Year Start
%A Whiteman, Maura K.; Oduyebo, Titilope; Zapata, Lauren B.; Walker, Seth; Curtis, Kathryn M.
%T Contraceptive safety among women with cystic fibrosis: a systematic review.
%J Contraception
%D 06/2016
%M ENG
%B With dramatic improvements in life expectancy for cystic fibrosis (CF) patients, contraception for women with CF has become an important issue. There are theoretical concerns that hormonal contraceptive use among women with CF may impact disease severity or risk for other adverse health outcomes, including thrombosis and poor bone health, as well as concerns that malabsorption or altered drug metabolism might impact contraceptive effectiveness.
%Y 10.1016/j.contraception.2016.05.016
%W PHY
%G AUTHOR
%R 2016..............W

@Article{Whiteman2016,
author="Whiteman, Maura K.
and Oduyebo, Titilope
and Zapata, Lauren B.
and Walker, Seth
and Curtis, Kathryn M.",
title="Contraceptive safety among women with cystic fibrosis: a systematic review.",
journal="Contraception",
year="2016",
month="Jun",
day="07",
abstract="With dramatic improvements in life expectancy for cystic fibrosis (CF) patients, contraception for women with CF has become an important issue. There are theoretical concerns that hormonal contraceptive use among women with CF may impact disease severity or risk for other adverse health outcomes, including thrombosis and poor bone health, as well as concerns that malabsorption or altered drug metabolism might impact contraceptive effectiveness.",
issn="1879-0518",
doi="10.1016/j.contraception.2016.05.016",
url="http://www.ncbi.nlm.nih.gov/pubmed/27287694",
language="ENG"
}

%0 Journal Article
%T Contraceptive safety among women with cystic fibrosis: a systematic review.
%A Whiteman, Maura K.
%A Oduyebo, Titilope
%A Zapata, Lauren B.
%A Walker, Seth
%A Curtis, Kathryn M.
%J Contraception
%D 2016
%8 Jun 07
%@ 1879-0518
%G ENG
%F Whiteman2016
%X With dramatic improvements in life expectancy for cystic fibrosis (CF) patients, contraception for women with CF has become an important issue. There are theoretical concerns that hormonal contraceptive use among women with CF may impact disease severity or risk for other adverse health outcomes, including thrombosis and poor bone health, as well as concerns that malabsorption or altered drug metabolism might impact contraceptive effectiveness.
%U http://dx.doi.org/10.1016/j.contraception.2016.05.016
%U http://www.ncbi.nlm.nih.gov/pubmed/27287694

PT Journal
AU Whiteman, MK
   Oduyebo, T
   Zapata, LB
   Walker, S
   Curtis, KM
TI Contraceptive safety among women with cystic fibrosis: a systematic review.
SO Contraception
PD Jun
PY 2016
DI 10.1016/j.contraception.2016.05.016
LA ENG
AB With dramatic improvements in life expectancy for cystic fibrosis (CF) patients, contraception for women with CF has become an important issue. There are theoretical concerns that hormonal contraceptive use among women with CF may impact disease severity or risk for other adverse health outcomes, including thrombosis and poor bone health, as well as concerns that malabsorption or altered drug metabolism might impact contraceptive effectiveness.
ER

PMID- 27287694
OWN - NLM
STAT- Publisher
DA  - 20160617
LR  - 20160617
IS  - 1879-0518 (Electronic)
IS  - 0010-7824 (Linking)
DP  - 2016 Jun 7
TI  - Contraceptive safety among women with cystic fibrosis: a systematic review.
LID - S0010-7824(16)30115-9 [pii]
LID - 10.1016/j.contraception.2016.05.016 [doi]
AB  - BACKGROUND: With dramatic improvements in life expectancy for cystic fibrosis
      (CF) patients, contraception for women with CF has become an important issue.
      There are theoretical concerns that hormonal contraceptive use among women with
      CF may impact disease severity or risk for other adverse health outcomes,
      including thrombosis and poor bone health, as well as concerns that malabsorption
      or altered drug metabolism might impact contraceptive effectiveness. OBJECTIVE:
      To evaluate evidence on the safety and effectiveness of contraceptive methods
      among women with CF. SEARCH STRATEGY: We searched the PubMed database for all
      articles published from database inception through October 2015. SELECTION
      CRITERIA: We included studies that examined measures of disease severity, other
      health outcomes or indicators of contraceptive effectiveness among women with CF 
      initiating or continuing a contraceptive method. RESULTS: Seven studies met our
      inclusion criteria. Three observational studies of fair to poor quality suggest
      that use of oral contraceptives (OCs) does not negatively impact CF disease
      severity, defined as changes in pulmonary function, number of exacerbations or
      need for intravenous antibiotics. Three small studies of poor quality reported on
      contraceptive failure among women with CF using combined hormonal contraceptives 
      (combined OCs, patch or ring). One pregnancy was reported in a patch user out of 
      43 hormonal contraceptive users across all studies. One pharmacokinetic study
      reported that women with CF achieve steroid hormone plasma concentrations similar
      to healthy women after ingestion of combined OCs. CONCLUSIONS: Limited evidence
      suggests that hormonal contraceptive use does not negatively impact disease
      severity among women with CF and that hormonal contraceptive effectiveness is not
      impaired by CF. Studies were limited by small sample sizes and short duration of 
      follow-up. No studies examined the effect of hormonal contraception on thrombosis
      or bone health among women with CF.
CI  - Published by Elsevier Inc.
FAU - Whiteman, Maura K
AU  - Whiteman MK
AD  - Division of Reproductive Health, National Center for Chronic Disease Prevention
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA,
      USA. Electronic address: [email protected]
FAU - Oduyebo, Titilope
AU  - Oduyebo T
AD  - Division of Reproductive Health, National Center for Chronic Disease Prevention
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA,
      USA.
FAU - Zapata, Lauren B
AU  - Zapata LB
AD  - Division of Reproductive Health, National Center for Chronic Disease Prevention
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA,
      USA.
FAU - Walker, Seth
AU  - Walker S
AD  - Emory University Adult Cystic Fibrosis Program, Atlanta, GA, USA.
FAU - Curtis, Kathryn M
AU  - Curtis KM
AD  - Division of Reproductive Health, National Center for Chronic Disease Prevention
      and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA,
      USA.
LA  - ENG
PT  - REVIEW
PT  - JOURNAL ARTICLE
DEP - 20160607
TA  - Contraception
JT  - Contraception
JID - 0234361
OTO - NOTNLM
OT  - Contraception
OT  - Cystic fibrosis
OT  - Effectiveness
OT  - Safety
OT  - Systematic review
EDAT- 2016/06/12 06:00
MHDA- 2016/06/12 06:00
CRDT- 2016/06/12 06:00
PHST- 2016/02/12 [received]
PHST- 2016/05/27 [revised]
PHST- 2016/05/29 [accepted]
AID - S0010-7824(16)30115-9 [pii]
AID - 10.1016/j.contraception.2016.05.016 [doi]
PST - aheadofprint
SO  - Contraception. 2016 Jun 7. pii: S0010-7824(16)30115-9. doi:
      10.1016/j.contraception.2016.05.016.
TY  - JOUR
AU  - Whiteman, Maura K.
AU  - Oduyebo, Titilope
AU  - Zapata, Lauren B.
AU  - Walker, Seth
AU  - Curtis, Kathryn M.
PY  - 2016/Jun/07
TI  - Contraceptive safety among women with cystic fibrosis: a systematic review.
JO  - Contraception
N2  - With dramatic improvements in life expectancy for cystic fibrosis (CF) patients, contraception for women with CF has become an important issue. There are theoretical concerns that hormonal contraceptive use among women with CF may impact disease severity or risk for other adverse health outcomes, including thrombosis and poor bone health, as well as concerns that malabsorption or altered drug metabolism might impact contraceptive effectiveness.
SN  - 1879-0518
UR  - http://dx.doi.org/10.1016/j.contraception.2016.05.016
UR  - http://www.ncbi.nlm.nih.gov/pubmed/27287694
ID  - Whiteman2016
ER  - 
<?xml version="1.0" encoding="UTF-8"?>
<b:Sources SelectedStyle="" xmlns:b="http://schemas.openxmlformats.org/officeDocument/2006/bibliography"  xmlns="http://schemas.openxmlformats.org/officeDocument/2006/bibliography" >
<b:Source>
<b:Tag>Whiteman2016</b:Tag>
<b:SourceType>ArticleInAPeriodical</b:SourceType>
<b:Year>2016</b:Year>
<b:Month>Jun</b:Month>
<b:Day>7</b:Day>
<b:PeriodicalName>Contraception</b:PeriodicalName>
<b:Author>
<b:Author><b:NameList>
<b:Person><b:Last>Whiteman</b:Last><b:First>Maura</b:First><b:Middle>K</b:Middle></b:Person>
<b:Person><b:Last>Oduyebo</b:Last><b:First>Titilope</b:First></b:Person>
<b:Person><b:Last>Zapata</b:Last><b:First>Lauren</b:First><b:Middle>B</b:Middle></b:Person>
<b:Person><b:Last>Walker</b:Last><b:First>Seth</b:First></b:Person>
<b:Person><b:Last>Curtis</b:Last><b:First>Kathryn</b:First><b:Middle>M</b:Middle></b:Person>
</b:NameList></b:Author>
</b:Author>
<b:Title>Contraceptive safety among women with cystic fibrosis: a systematic review.</b:Title>
<b:Comments>With dramatic improvements in life expectancy for cystic fibrosis (CF) patients, contraception for women with CF has become an important issue. There are theoretical concerns that hormonal contraceptive use among women with CF may impact disease severity or risk for other adverse health outcomes, including thrombosis and poor bone health, as well as concerns that malabsorption or altered drug metabolism might impact contraceptive effectiveness.</b:Comments>
</b:Source>
</b:Sources>